A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate the efficacy of SKL11197 for the treatment of diabetic
peripheral neuropathy pain (DPN).
Secondary Objective: To evaluate the safety and tolerability of SKL11197 in subjects with
painful diabetic peripheral neuropathy.
Primary Efficacy Endpoint: The primary efficacy outcome variable will be the time to exit
from the double-blind phase because of inadequate pain relief.